Webinar Series: Finding Balance in Treating POAG or OHTN

Practice guidelines recommend balancing IOP-lowering efficacy with tolerability and other health concerns in patients with POAG or OHTN.1,2,3,4 But, what are your options?

On behalf of Sucampo Pharma Americas, LLC, we invite you to join us for a webinar series that explores approaches to treatment for your practice.

Topics covered may include:
• Glaucoma prevalence and the aging populationregister
• Unique safety considerations in elderly patients
• Individualizing treatment
• RESCULA and its use in clinical practice

RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

RESCULA is contraindicated in patients with hypersensitivity to unoprostone isopropyl or any other ingredient in this product.

Adverse Reactions
In clinical studies, the most common ocular adverse reactions (incidence 10-25%) with use of RESCULA were burning/stinging, burning/stinging upon drug instillation, dry eyes, itching, increased length of eyelashes, and injection.


1. American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Pattern® guideline. Primary open-angle glaucoma. San Francisco, CA: American Academy of Ophthalmology; 2010. www.aao.org/ppp. Accessed August 8, 2012. 2. Fingeret M. American Optometric Association Original Consensus Panel on Care of the Patient with Open Angle Glaucoma. Optometric clinical practice guideline: care of the patient with open angle glaucoma. American Optometric Association, 2010. HYPERLINK http://www.aoa.org/documents/QRG-9.pdf www.aoa.org/documents/QRG-9.pdf. Accessed August 8, 2012 3. Gottfredsdottir MS, Allingham RR, Shields MB. Physicians’ guide to interactions between glaucoma and systemic medications. J Glaucoma. 1997;6(6):377-383. 4. RESCULA [package insert]. Bethesda, MD: Sucampo Pharmaceuticals, Inc; 2012. 4. Xalatan prescribing information. NewYork, NY: Pfizer Inc; 2011.

This program is being sponsored by Sucampo Pharma Americas, LLC.
The presenter is speaking on behalf of Sucampo Pharma Americas, LLC.

Available Webinars